BRITISH MAESTRO AAKASH ODEDRA ON LIFE IN LOCKDOWN AND HIS NEW SHOW
by ASJAD NAZIR
THE last decade has been quite extraordinary for acclaimed British dancer Aakash Odedra.
The fabulously fleet-footed talent has gone from superb shows like his full-length solo debut Rising to setting up a dynamic company that has delivered exciting work and helped expand the horizons of classical Indian dance. The rapid rise has enabled him to perform all over the world, light up major venues and collaborate with artistic giants.
The widely acclaimed dancer and choreographer was due to carry on that impressive momentum in 2020 with thrilling new show Samsara, but one of the year’s most highly anticipated tours was halted by the Covid-19 virus.
So, while he may fly like a free bird onstage, the classically trained dancer has had his wings clipped by the pandemic like the rest of the world and has been stuck indoors. But it hasn’t stopped him from learning more about himself.
Eastern Eye caught up with Aakash Odedra to talk about his thrilling journey as a performer, his stunning-looking new show Samsara, the unique way in which he has spent lockdown and future hopes.
How do you look back on your journey in dance?
It depends on which point of my life I focus on. My journey ‘officially’ spans 28 years and, in that time, I have been pushed and pulled by the currents of the ocean. Sometimes I have been washed ashore on uncharted territories, other times I have landed on familiar ground. The further my boat sails, the more knowledge and understanding I have when I look back on my past. Each story seems to progress more with time, some chapters open and close, others urge me to search deeper within.
How much has lockdown disrupted your plans?
Every disruption is an indication of the good to come. After being on a hamster wheel for the last 12 years, I welcomed the abrupt stop. As an artist, I feel we have a natural synchronicity with nature and it’s evident that we are being urged to stop and re-evaluate. I think we all have to recalibrate and realign ourselves with a new state of mind.
What have you been doing?
Lockdown gave me the opportunity to go into deep meditation to find answers for questions I have been asking myself for a while now. I locked myself in my room with no food or water, sitting in one place for three days, meditating. The process of observation, the chance to trace the path of my thoughts back to their origin, was remarkable. For me, I realised that it’s not lockdown that has been disruptive. Rather, we have disrupted our own inner patterns and thoughts through unnecessary desires, focusing on what we want rather than what we need.
What have you been doing during lockdown in terms of dance?
Nothing! I have hardly danced and taken the opportunity to rejuvenate, mentally and spiritually. I have found creative expression in watching a seedling grow in the garden and blossom. That doesn’t mean my participation has been passive, on the contrary, I’ve been actively observant. The time has come for me to invent new rules and new pathways, not to retread old roads. For me, dance represents life; it’s a mirror to all our experiences, a reflection of honesty, fragility and humanity. We can’t expect to speak to the world about life if we have become ignorant of it or are too self-absorbed in rehearsals or emails. By nourishing the soul and mind, we can organically reset ourselves. Change doesn’t need to be revolutionary and can be like a minute whisper that carries its message on the wind.
How much of a disappointment is it that you could not premiere your latest work Samsara?
If I have learnt anything in the last few months, it’s to expect the unexpected, or even better, don’t expect anything at all. For me, it was an achievement and a miracle that Samsara premiered at the Asia TOPA Festival in Melbourne. We suffered greatly as a company during the build-up because my fellow performer, Hu Shenyuan, was Chinese. The world started locking its borders; we had to move swiftly and didn’t know if it would be possible for him to be part of the production that we had worked on together for three years. In the end, we premiered it with Hu against all the odds. The experience was priceless, not disappointing.
When can we expect to see Samsara?
It’s a waiting game – but a game for which I hold no expectations.
Tell us something about your new work?
Samsara, inspired by the classic Chinese novel Journey to the West, traces the steps we take, both forward and backward, in search of our higher selves. It’s an epic, highly visual, mythological story. It draws on the thinking and imagery at the heart of Buddhist philosophy and explores some of the 81 obstacles and six states of mind that can hold us back.
What inspired this new piece?
The story of Journey to the West, a monk who took 14 years to walk from China to India to find original Buddhist scriptures and knowledge, became the key point of interest for us. We were fascinated to think that hundreds of years ago there was a need for cultural interdependency to further one’s own civilisation and understanding. It’s ironic that today, when we have easy access to transport, the nations’ walls seem to be getting higher and higher, and the thirst for learning about other cultures seems to be rapidly diminishing with time.
What is the dance master plan going forward?
I don’t make master plans! I let the plans make me.
You have achieved a lot in a short space of time, but do you have one big unfulfilled dance ambition?
I feel I haven’t achieved anything and that is why my life’s book still has commas, dashes and many continuing dots. So the search continues, maybe with dance, maybe without.
The expectations around you are high; do you feel the pressure?
Yes, at times it does, because I am not a demigod, I am only human. It’s hard to be objective when you yourself are the object. I often look at the audience from the wings before a performance and try to understand why they have come to watch me. I have never been able to answer that question, but I try to give my all to the observers when I perform hoping that, even if it was a passing moment, we had some level of exchange. That way, I also put a lot of pressure on myself.
How do you feel performing on stage?
I don’t have the words to describe it and that’s why I dance.
Your most memorable performance?
Performing in front of my gurus in Mumbai in India in 2016.
What has been your most memorable collaboration in dance?
Working with a living legend, Aditi Mangaldas, on Echoes, the solo she created on me. I idolise her – the way she moves, thinks, explores and talks. I felt that every second I spent with her was like a day in the university of life and dance. She is dance!
What advice would you give aspiring dancers?
Who am I to give advice? All I can say in simple terms is that there’s a reason you have come this far in life. Don’t give up, keep moving up.
What are your big passions away from dance?
Animals, gardening, decorating, eating, documentaries, walks in the countryside, history, reading books, talking, joking and laughing with my inner circle of friends. The list goes on.
Shefali Jariwala died at 42 in Mumbai after reportedly collapsing post-fast; cause of death suspected to be cardiac arrest or blood pressure drop.
Police found anti-ageing pills, vitamin supplements, and glutathione injections at her residence.
Doctors stress the risks of unsupervised use of hormone-based and anti-ageing treatments.
Final post-mortem report expected in two days; no foul play suspected, case treated as accidental death.
The untimely death of actor-model Shefali Jariwala has sparked renewed concern over the unregulated use of anti-ageing treatments and self-medication. The 42-year-old, best known for her appearance in Kaanta Laga, was declared dead on arrival at a Mumbai hospital on Friday night. Initial investigations suggest she may have suffered a cardiac arrest following a steep drop in blood pressure, possibly linked to taking supplements on an empty stomach.
Shefali Jariwala death raises concern over anti ageing drugs and self medication Instagram/shefalijariwala
What caused Shefali Jariwala’s collapse? Police and doctors investigate
Shefali Jariwala was rushed to Bellevue Multispeciality Hospital by her husband and friends after she suddenly collapsed at home, but she was already unresponsive. Her family said she had been fasting for a religious ritual and had consumed her regular supplements shortly after breaking the fast. Among the substances recovered at her Andheri apartment were glutathione injections, commonly used for skin lightening, and various anti-ageing tablets.
Doctors at Cooper Hospital, where her post-mortem was conducted, suspect a fatal drop in blood pressure, though only the final autopsy will confirm the precise cause of death. So far, Mumbai Police have ruled out foul play and registered an accidental death report.
Health experts warn against unmonitored anti-ageing therapies
Experts are now urging caution over the growing trend of unsupervised beauty and anti-ageing regimens, especially among public figures. Dr Dhirendra Singhania, a leading cardiologist, pointed to steroids, hormone therapies, and poor sleep as major heart risk factors, even among seemingly fit individuals. While glutathione and vitamin C aren’t inherently dangerous, he said their misuse or interaction with other drugs can trigger complications.
Anti ageing pills found at Shefali Jariwala home spark health safety debate Instagram/shefalijariwala
Shefali had no known chronic illnesses apart from epilepsy, which doctors say is unlikely to be linked to her sudden collapse. Her death, while still under investigation, adds to growing concerns about beauty pressures, self-prescribed treatments, and the long-term risks of trying to defy ageing without medical oversight.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear
• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy • Indian artisans and officials accused the brand of cultural appropriation • The footwear resembles traditional Kolhapuri chappals with GI status • Prada says designs are still in development and open to dialogue with India
Italian fashion label Prada has officially acknowledged that its Spring/Summer 2026 menswear collection includes footwear inspired by India’s traditional Kolhapuri chappals. The statement came after mounting criticism from Indian artisans and industry leaders, who claimed the brand showcased the design at Milan Fashion Week without recognising its origins.
Prada confirms Kolhapuri chappals inspired its 2026 Milan collectionInstagram/prada
Prada responds to Kolhapuri chappal row
In a letter addressed to Lalit Gandhi, President of the Maharashtra Chamber of Commerce, Industry and Agriculture (MACCIA), Prada’s CSR head Lorenzo Bertelli confirmed the sandals were influenced by Indian craftsmanship. The fashion house admitted that the open-toe leather sandals presented on the Milan runway drew from the centuries-old Kolhapuri style, traditionally made by artisans in Maharashtra and Karnataka.
Kolhapuri chappals have been crafted for centuries and received GI tag in 2019 iStock
The controversy erupted after Prada described the footwear simply as “leather sandals” in its show notes, omitting any reference to India. This led to accusations of cultural appropriation and disregard for artisans' rights. BJP MP Dhananjay Mahadik also led a group of Kolhapuri chappal makers to meet Maharashtra Chief Minister Devendra Fadnavis, urging government action to protect their Geographical Indication (GI) status.
No production yet, says Prada, as India seeks fair credit
Prada clarified that the sandals shown were part of an early-stage design process and have not been confirmed for mass production. “None of the pieces are finalised or approved for commercial use,” Bertelli wrote.
MACCIA, in its communication, called for proper acknowledgement and possible collaboration or compensation for Indian artisans. The organisation stressed that Kolhapuri chappals are not just heritage products but also vital to the livelihoods of thousands of families.
In response, Bertelli assured Prada’s commitment to ethical design, cultural respect, and further engagement with Indian artisan communities. He also welcomed the opportunity for open dialogue on potential partnerships.
The Kolhapuri chappal, awarded GI status in 2019, is a symbol of regional identity and craftsmanship. As global fashion continues to borrow from traditional cultures, this case may set the tone for how brands address ownership, recognition, and respect.
Keep ReadingShow less
Wintour’s style of leadership earned her the nickname “Nuclear Wintour”
Anna Wintour steps down as editor of US Vogue after 37 years
She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
Wintour transformed US Vogue into a global fashion authority
The 75-year-old has received numerous honours, including the Presidential Medal of Freedom
End of an era at US Vogue
Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.
The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.
A transformative legacy
Wintour took the helm of US Vogue in 1988, inheriting a relatively conservative magazine. She swiftly transformed it into a trendsetting, authoritative voice in fashion. Under her leadership, the publication became known for its iconic covers, high-end photography, and ability to shape careers in the fashion industry.
With extensive budgets and strong advertising support, Vogue became a global fashion flagship, influencing designers, celebrities, and brands worldwide.
Wintour’s style of leadership earned her the nickname “Nuclear Wintour” for her decisiveness, with some reports noting her tendency to make bold editorial decisions without extensive discussion. Her distinctive bob haircut and ever-present sunglasses made her a recognisable front-row figure at fashion weeks around the world.
Beyond the magazine
The British-born editor rose to wider public fame as the inspiration behind the character Miranda Priestly in The Devil Wears Prada — both the 2003 novel and the 2006 film adaptation. While Wintour rarely commented on the portrayal, she acknowledged the attention it brought, most recently during the launch of a stage musical adaptation in London in 2024.
She told the BBC, “They [my sunglasses] help me see and they help me not see. They help me be seen and not be seen. They are a prop, I would say.”
Wintour also became synonymous with the Met Gala, the annual high-profile charity event in New York City, which she has organised for years, drawing celebrities from fashion, film, politics, and sport.
Recognition and future plans
Wintour has received numerous accolades during her career. She was made a Dame Commander of the Order of the British Empire (DBE) in 2017 and became a Companion of Honour in February 2025. During the ceremony in London, she removed her sunglasses to receive the award and told King Charles III that she had no intention of retiring.
Wintour also became synonymous with the Met GalaGetty Images
In the United States, President Joe Biden awarded her the Presidential Medal of Freedom earlier this year before leaving office.
Despite stepping back from US Vogue, Wintour will continue to oversee several major Condé Nast titles including Wired, Vanity Fair, GQ, Condé Nast Traveler, and Glamour, as part of her global leadership responsibilities.
In her remarks to staff, she described the decision as “pivotal” but confirmed she would not be leaving the company or her office. “I’ll be turning all my attention to global leadership and working with our team of brilliant editors around the world,” she said.
Nadiya Hussain confirms BBC will not renew her cookery series
Bake Off winner challenges expectations to remain “grateful”
She says hard work and talent, not luck, brought her success
Celebrities, including Annie Lennox and Fearne Cotton, show support
BBC ends decade-long collaboration with Bake Off star
Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.
The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.
“Gratitude shouldn't be a muzzle”
In a video message posted on Instagram, Hussain said she had received numerous messages urging her to be grateful following the show's cancellation. She described how growing up in an immigrant household had shaped her understanding of gratitude.
“Grateful for being let in, grateful for having work—even if underpaid, grateful for safety—even if it meant silence,” she explained. “Gratitude became something that I was expected to wear like a uniform.”
She continued: “I am allowed to feel more than just thankful. I am a human being, and I am allowed to feel angry when I’m treated unfairly. I’m allowed to want better for myself and for my family.”
Challenging the idea that people from marginalised backgrounds must constantly express gratitude for any opportunities, she said: “We didn’t come here just to survive; we came here to live, to grow, to contribute, to belong—not as a guest, but as a person who has rights and dreams and dignity.”
Hussain concluded, “So no, I won’t always be grateful. I got here through hard work, through determination, through talent. I got here because I’m good at what I do.”
Nadiya’s message received widespread support from fans and fellow public figures. TV presenter Fearne Cotton responded with a series of heart emojis, while musician Annie Lennox praised her statement, writing: “Gratitude should never become a silencing muzzle—as you so rightly say!”
Rahul Mandal, who won Bake Off in 2018, commented: “So true. Thanks so much for speaking up.” TV doctor Amir Khan also backed her remarks, stating: “Exactly this! Well said.”
Nadiya’s track record with the BBC
Since winning Bake Off when it aired on the BBC, Hussain has fronted several successful cookery series for the broadcaster. These include Nadiya Bakes, Nadiya’s Fast Flavours, and Nadiya’s Simple Spices. She is also a published author of cookbooks and children’s titles.
Earlier this month, the BBC issued a statement on the programming decision: “After several wonderful series, we have made the difficult decision not to commission another cookery show with Nadiya Hussain at the moment.”
However, the broadcaster emphasised that it remains open to future collaborations and that Nadiya is “a much-valued part of the BBC family”.
What’s next for Nadiya?
While a new BBC project is not in the pipeline, Nadiya has hinted at future ventures. In a previous post addressing the show’s cancellation, she said she is now focusing on “being [her] most authentic self” and is looking forward to working with people who “believe in [her] talent”.
She also reassured her followers that “exciting” new projects are on the way.
Keep ReadingShow less
The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow
Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
Health officials are investigating possible genetic causes behind the side-effects
Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
Adverse drug reactions cost the NHS an estimated £2.2bn annually
Health watchdog investigates spike in serious side-effects from GLP-1 drugs
UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.
The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.
What is acute pancreatitis?
Acute pancreatitis is a sudden inflammation of the pancreas, the gland located behind the stomach that helps with digestion. Symptoms typically include severe abdominal pain, nausea, and fever, and the condition often requires hospital treatment. In rare cases, it can be fatal.
Though pancreatitis is listed as an “uncommon” side-effect of GLP-1 medications in patient information leaflets – meaning it may affect around one in 100 people – the MHRA has seen a notable rise in reported incidents, particularly in 2025.
Since the start of the year, there have been 22 reports involving semaglutide (Ozempic and Wegovy) and 101 involving tirzepatide (Mounjaro).
Study launched to explore potential genetic link
To understand the possible causes of these side effects, particularly in light of rising usage of these medications, the MHRA is inviting affected patients to take part in a research study through the Yellow Card Biobank. The initiative, run by Genomics England, will collect saliva samples and other data to explore any genetic factors that may be influencing patient response to GLP-1 drugs.
An MHRA spokesperson stated: “Alongside increased usage, we are seeing an upturn in the number of Yellow Card reports mentioning GLP-1 medicines and acute pancreatitis.”
While no known genetic link has yet been established, the MHRA said genetic variations could help explain why some patients experience adverse reactions to certain medications. The agency is urging both patients and health professionals to report suspected side-effects related to these drugs.
Adverse reactions place burden on NHS
Research shows that one in six hospital admissions is caused by an adverse drug reaction, and around a third of those could potentially be avoided through genetic testing. The financial cost is also significant – the NHS spends over £2.2 billion each year on hospital stays linked to adverse reactions alone.
Dr Alison Cave, chief safety officer at the MHRA, highlighted the need for more personalised approaches to medicine: “Evidence shows that almost a third of side-effects to medicines could be prevented with the introduction of genetic testing.”
Manufacturers respond to rising concerns
In response to the reports, drugmakers Lilly and Novo Nordisk reiterated their commitment to patient safety and advised that side effects should always be reported and discussed with healthcare professionals.
A spokesperson for Lilly, which manufactures Mounjaro, said: “Patient safety is Lilly’s top priority. We take reports seriously and actively monitor, evaluate and report safety information for all our medicines.”
The Mounjaro leaflet identifies acute pancreatitis as an uncommon side-effect, advising patients to consult their doctor before using the drug if they have a history of the condition.
Novo Nordisk UK, which produces Ozempic and Wegovy, issued a similar statement: “Patient safety is of the utmost importance to Novo Nordisk… The known risks and benefits of GLP-1 medicines are described in the product information. We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional.”
Both companies said they were continuously collecting safety data and working with authorities to ensure ongoing monitoring and understanding of their treatments.
What should patients do?
Health officials are encouraging patients who have experienced severe symptoms such as abdominal pain, nausea, or fever after taking these medications to report their experiences to the Yellow Card scheme. Hospitalised individuals may be contacted to participate in the Biobank study.
While the overall safety profile of GLP-1 medicines remains positive, the MHRA has stressed the importance of vigilance as demand for these weight loss and diabetes drugs continues to grow.